Melanotan 1: Suggested Uses and Ongoing Experiments
Melanotan 1 is sometimes called afamelanotide or NDP-MSH. It is a commercially synthesized analog of the naturally-produced hormone alpha melanocyte-stimulating hormone. Scientists at the University of Arizona first discovered the hormone. The peptide acts on the melanocortin producing system and it is important in the production of melanin through melanogenesis. Melanogenesis is an essential process, which ensures that the skin is not harmed by damaging ultraviolet rays of the sun. The melanotide peptide is currently under research for potential use in combating several conditions. It is important to note that melanotan 1 is vital in photoprotection and its use is still regulated. Most of the peptides available in the market are only for research purposes. Melanotan 1 has received attention from many enthusiasts across the globe as a sunless tanning injection. However, it is important to note that the melanotan 1peptides are solely for scientific research purposes and human consumption has not been approved.
Usage in EPP
Recent evidence indicates that melanotan 1 is a very effective and potent peptide that can treat erythropoietic photoporphyria. Research findings show that two out of three research organisms exhibited complete healing after the injection of the peptide in a regulated dosage. The symptoms of the condition were reduced drastically. The research findings indicated that the peptide could be a potential cure for the condition in the near future after clinical trials are conducted.
Effects on Tanning and Ultraviolet B Radiation Exposure Outcome
In the three-part series of trials conducted by the University of Arizona in 2005, melanotan 1 has demonstrated a significant effect in areas such as ultraviolet B radiation and tanning outcomes. The research findings show that majority of the test subjects received tanning and their sunburn cells are reduced by over 47%. In the second study, an increase in the dosage of melanotan 1 resulted in darkened sites on the organism of study. In the third study, maintaining a certain dosage of melanotan injections resulted in uniform tanning and no sun exposure. It is imperative to note that melanotan 1 is a research peptide and the studies are currently conducted on mice and guinea pigs. Reduction in sunburn cells and the lessened effects of ultraviolet exposure with long lasting tanning effects show that the potential of the melanotan peptide is yet to be achieved.
Future Possibilities of Melanotan I in Developmental and Translational Research
In essence, scientists have been looking for ways of combating various illnesses in a patient-centered manner. This is essential because the possibility of dealing with various conditions will be easier and the medication will have a profound effect when administered. The research done on porphyrias and ultraviolet sensitive conditions such as sunless tanning and depigmentation are some of the modern studies that melanotan 1 peptide could be put into use. Drug development is one of the biggest challenges and the delivery of a compound in a way that will bring about a therapeutic effect for a target population is challenging. Exploiting the target population is also a problem. However, emerging data shows that melanotan 1 has many other potential benefits that can be amassed to bring out its best.
The main challenge facing melanotan peptide research is the delivery system, the fact that the peptide has complex molecules that do not pass through epidermal cells because of its molecular characteristics or its fragile nature makes studying it difficult. Currently, scientists are using intramuscular, intravenous and subcutaneous as the main sources of entry. However, the route of delivery still poses a major challenge because the melanotan 1 efficiency falls immediately if delivered in the wrong route.
Melanotan 1 has a half-life of about one hour and this means that the peptide must be injected twice a day for the full effect to be seen. It is imperative to note that the peptide can only produce reactions when administered in the right way. The recommended research study dosage is 0.50mg or 500mcgs twice a day. As the days progress, a dosage increase may be recommended. This is important especially in research because you can identify the right melanotan dosage that brings about the desired outcome.
In the treatment of EPP, melanotan 1 with a dosage of 16mg has shown to be effective in alleviating the toxicity without regular administration. Since the peptide has a shorter half-life, scientists have devised a way of introducing it in large quantities in regular dosage to allow the peptide to perform optimally. It is important to note that the trials are being conducted on guinea pigs and mice because they are closely related to humans. The endogenous alpha melanocyte stimulating hormone plays a very crucial role in the mammalian physiology. The diverse effects of melanotan 1 hold a possible research and benefits, which include
Suggested Cardiac Research with Melanotan 1
In previous studies, research on guinea pigs has indicated that melanotan 1 could have cardioprotective features. In modern research, scientists are looking for a way to replicate the result on a large scale with better functionality. Studies revealed that the peptide could protect the test subject from heart reperfusion injuries especially during transplantation. In addition, changes occurred during the study also suggested that the ischemic preconditioning with melanotan 1 reduced the chance of developing organ transplant. Conditioning plays an effective role and leads to a smaller myocardial infarction compared to other normal transplants. The melanocortin 1 receptors mediate a general anti-inflammatory effect on the test subject. The studies are, however, still ongoing and a solution to the problem could be found soon.
Suggested Anti-Melanoma Research with Melanotan 1
Melanotan 1 has been seen to have anti-inflammatory effects anti-oxidant effects. This is mediated by the transcription factor Nrf2. Any transcriptional modification conducted on the synthesis of the protein could result in overall changes of the peptide response. Melanotan 1 have also been suggested to have preventive benefits if it is administered in the right dosage. The effects of bremelanotide 1 on the magnitude caused by effects of ultraviolet rays exposure shows that melanotan 1 has more precise and beneficial effects in preventing uncontrolled cellular division. In preliminary results, studies showed that among the markets in seventeen human melanoma cells, the upregulation of tyrosinase activity results in cell size changes and enzymatic exposure also varies during the incubation period. Melanotan 1 has demonstrated to have apparent anti-proliferative effects in the expression of melanocortin receptors, especially those cancerous cells. Studies revealed that the peptide has a remarkable effect on some strains of human melanoma cell lines.